Evosep launches Eno platform targeting next-generation proteomics workflows
Evosep has unveiled its latest separation technology, the Evosep Eno™, designed to advance high-throughput LC-MS proteomics for pharmaceutical and biotech applications. The announcement, made at the Annual Conference on Mass Spectrometry (ASMS) in Baltimore, positions the platform as a cornerstone technology for next-generation proteomics workflows.
Enhanced throughput meets precision analysis
The Evosep Eno delivers substantial performance improvements, offering 40% enhanced performance whilst maintaining increased accuracy and precision in protein quantification. The system enables analysis of more than 500 samples per day, with capabilities extending to over 2000 proteins per minute – a throughput previously unattainable in routine proteomics applications.
Prof Jesper V. Olsen from the University of Copenhagen highlighted the platform’s capabilities: “The new Evosep Eno will make a big impact in the next generation of LC-MS based proteomics. With the new Evosep Eno we can analyse more than 500 samples per day which was impossible before and identify close to 7000 proteins and quantify 70,000 precursors, so that’s absolutely amazing.”
Standardisation drives reproducibility
The platform addresses critical challenges in multi-site proteomics studies through industry-leading system-to-system and lab-to-lab reproducibility. Standardised workflows with integrated consumable solutions streamline processes whilst reducing operational errors, supporting academic research centres, drug developers, and contract research organisations.
Strategic partnerships expand market reach
Alongside the Eno launch, Evosep has established a reseller agreement with SCIEX to support pharmaceutical companies in analysing broader drug modalities more efficiently and at greater scale.
“The Evosep Eno is a key component of the next generation LC-MS based proteomics workflows. Its capabilities will empower researchers to uncover new insights and drive progress in drug discovery and translational research,” said Nicolai Bache, VP Proteomics Research at Evosep.
For more information, visit: www.evosep.com
Digital issue: Please click here
for more information
